There has been some preliminary research in the 1960's. From "The neurobiology of psychedelic drugs: implications for the treatment of mood disorders" by Vollenweider and Kometer:
Psycholytic therapy was introduced by Ronald Sandison and applied in
Europe at 18 treatment centres. In psycholytic therapy, low to
moderate doses of LSD (50–100 μg), psilocybin (10–15 mg) or,
sporadically, ketamine were used repeatedly as an adjunct in
psychoanalytically oriented psychotherapy to accelerate the
therapeutic process by facilitating regression and the recollection
and release of emotionally loaded repressed memories, and by
increasing the transference reaction. A review of 42
studies reported impressive improvement rates in (mostly
treatment-resistant) patients with anxiety disorders (improvement in
70% of patients), depression (in 62% of patients), personality
disorders (in 53–61% of patients), sexual dysfunction (in 50% of
patients) and obsessive–compulsive disorders (in 42% of patients).
Unfortunately, the majority of these studies had serious
methodological flaws by contemporary standards. In particular, with
the absence of adequate control groups and follow-up measurements and
with vague criteria for therapeutic outcome, the studies did not
clearly establish whether it was the drug or the therapeutic
engagement that produced the reported beneficial effect. It was also
difficult to draw firm conclusions regarding potential long-term
efficacy. Nevertheless, the studies provide a conceptual framework for
the application of psychedelics, with the data suggesting that the
most promising indication for psychedelic use might be found in the
treatment of depression and anxiety disorders.
